177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment ; volume:18 ; number:04 ; year:2019 ; pages:406-408
World Journal of Nuclear Medicine ; 18, Heft 04 (2019), 406-408
- Beteiligte Personen und Organisationen
- DOI
-
10.4103/wjnm.WJNM_112_18
- URN
-
urn:nbn:de:101:1-2022060911304422936686
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Assadi, Majid
- Ahmadzadehfar, Hojjat
Ähnliche Objekte (12)
90Y/177Lu-DOTATATE therapy: survival of the fittest?
Tissue dose estimation after extravasation of 177Lu-DOTATATE
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
Lymphopenia during 177Lu-DOTATATE therapy leading to recurrence of tuberculosis: a case report
Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days
90Y/177Lu-DOTATATE therapy: survival of the fittest?
Tissue dose estimation after extravasation of 177Lu-DOTATATE
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
Lymphopenia during 177Lu-DOTATATE therapy leading to recurrence of tuberculosis: a case report
Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days
90Y/177Lu-DOTATATE therapy: survival of the fittest?
Tissue dose estimation after extravasation of 177Lu-DOTATATE
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
Lymphopenia during 177Lu-DOTATATE therapy leading to recurrence of tuberculosis: a case report
Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours